Skip to content
DataLookout
Menu

NCT07943221

Study Evaluating Safety & Tolerability of Migaldendranib in US Healthy Volunteers

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Timeframe: Varying timepoints through end of treatment, up to approximately 29 days per cohort.

Secondary (6)

Pharmacokinetic Parameter Area Under the Curve (AUC) for MGB
Pharmacokinetic Parameter Maximum Concentration (Cmax) for MGB
Pharmacokinetic Parameter Total Clearance (CL) for MGB
Pharmacokinetic Parameter Apparent Terminal Half-life (t1/2) for MGB
Pharmacokinetic Parameter Time to Maximum Plasma Concentration (tmax) for MBG
Show 1 moreShow less
Pharmacokinetic Parameter Apparent Terminal Rate Constant (kel) for MGB

Arms and interventions

MGB 200 mg Formulation 1Experimental

Participants receive MGB 200 mg Formulation 1 administered subcutaneously once weekly on Days 1, 8, and 15 to evaluate safety, tolerability, and pharmacokinetics.

MGB 200 mg Formulation 2Experimental

Participants receive MGB 200 mg Formulation 2 administered subcutaneously once weekly on Days 1, 8, and 15 to evaluate safety, tolerability, and pharmacokinetics.

MGB 400 mgExperimental

Participants receive MGB 400 mg administered subcutaneously once weekly on Days 1, 8, and 15 following Safety Review Committee approval.

Experimental: To Be Determined (Optional Arm)Experimental

This optional arm will be used if recommended by the Safety Review Committee. Dosage TBD.

Drugs: Weekly subcutaneous administration of Migaldendranib (MGB)

Sites

1 site in 1 country

  • Medpace Clinical Pharmacology UnitCincinnati, Ohio, United States